P38 inhibition in COPD; cautious optimism

Thorax

Volumn 68, Issue 8, 2013, Pages 705-706

  Singh, Dave ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; GLUCOCORTICOID RECEPTOR; LOSMAPIMOD; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PH 797804; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR;

BRONCHOSCOPY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; EMPHYSEMA; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; LIVER TOXICITY; LUNG FUNCTION; MACROPHAGE; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SPUTUM ANALYSIS;

COPD PHARMACOLOGY;

BENZAMIDES; FEMALE; HUMANS; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDONES;

EID: 84879989325     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203498     Document Type: Editorial

References (19)

1. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
2. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
3. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5.
4. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
5. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7. (Pubitemid 38987064)
6. Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011;338:732-40.
7. Moretto N, Bertolini S, Iadicicco C, et al. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 2012;303:L929-38.
8. Gaffey K, Reynolds S, Plumb J, et al. Increased phosphorylated p38 mitogen activated protein kinase in COPD lungs. Eur Respir J Published Online First: 11 October 2012. doi:10.1183/09031936.00170711
9. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9.
10. Singh D, Smyth L, Borrill Z, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010;50:94-100.
11. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012;52:416-24.
12. Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011;38:846-54.
13. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010;69:i77-82.
14. Hope HR, Anderson GD, Burnette BL, et al. Anti-inflammatory properties of a novel N -phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 2009.
15. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006; 149:393-404. (Pubitemid 44582246)
16. Macnee W, Allan RJ, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013;68:738-45.
17. Lemire BB, Debigaré R, Dubé A, et al. MAPK signaling in the quadriceps of patients with chronic obstructive pulmonary disease. J Appl Physiol 2012;113:159-66.
18. Riddoch-Contreras J, George T, Natanek SA, et al. p38 mitogen-activated protein kinase is not activated in the quadriceps of patients with stable chronic obstructive pulmonary disease. COPD 2012;9:142-50.
19. Abraham SM, Lawrence T, Kleiman A, et al. Anti-inflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203:1883-9. (Pubitemid 44188463)